Table 1.
Comparison of CRISP and HALT Study A cohorts by baseline characteristics
| CRISP | HALT Study A | |
|---|---|---|
| Total no. patients | 237 | 528 |
| Age (yr) | 32.3 ± 8.8 | 36.3 ± 8.3 |
| Sex (% male) | 39.7% | 51.9% |
| Race | ||
| Caucasian | 86.5% | 92.2% |
| African-American | 11.4% | 2.7% |
| Height (cm) | 172.0 ± 11.0 | 174.0 ± 10.3 |
| BMI (kg/m2) | 25.8 ± 5.2 | 27.1 ± 5.2 |
| Office SBP (mm Hg) | 123.1 ± 13.1 | 126.8 ± 13.9 |
| Office DBP (mm Hg) | 79.4 ± 10.5 | 80.1 ± 11.1 |
| htTKV (ml/m) | 616±371 | 685 ± 394 |
| eGFR* | 92.4± 22.9 | 91.6 ± 17.6 |
| PKD genotype | ||
| PKD1 | 78.7% | 76.2% |
| PKD2 | 14.0% | 15.1% |
| NMD | 7.2% | 8.7% |
| Mutation type† | ||
| Truncating PKD1 | 58.6% | 51.5% |
| Non-truncating PKD1 | 27.6% | 30.5% |
| Truncating PKD2 | 10.48% | 14.4% |
| Non-truncating PKD2 | 3.3% | 3.6% |
*
By CKD EPI formula (mL/min/1.73 m2)
†
In patients with detectable PKD1 or PKD2 mutations
htTKV, height-adjusted total kidney volume; eGFR, estimated GFR from serum creatinine by CKD-Epi equation; NMD, no mutation detected